Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B

Marcellin, P; Lau, GKK; Bonino, F; Farci, P; Hadziyannis, S; Jin, R; Lu, ZM; Piratvisuth, T; Germanidis, G; Yurdaydin, C; Diago, M; Gurel, S; Lai, MY; Button, P; Pluck, N

doi:10.1056/nejmoa040431

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B

Marcellin P., Lau G., Bonino F., Farci P., Hadziyannis S., Jin R., ...More

NEW ENGLAND JOURNAL OF MEDICINE, vol.351, no.12, pp.1206-1217, 2004 (SCI-Expanded, Scopus)

Publication Type: Article / Article
Volume: 351 Issue: 12
Publication Date: 2004
Doi Number: 10.1056/nejmoa040431
Journal Name: NEW ENGLAND JOURNAL OF MEDICINE
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.1206-1217
Open Archive Collection: AVESIS Open Access Collection
Ankara University Affiliated: No

Abstract

Background: Available treatments for hepatitis B e antigen (HBeAg)-negative chronic hepatitis B are associated with poor sustained responses. As a result, nucleoside and nucleotide analogues are typically continued indefinitely, a strategy associated with the risk of resistance and unknown long-term safety implications.